Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

NCT05024552 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation

Interventions

DRUG: Gilteritinib
DRUG: Vyxeos

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]